The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Treatment outcomes for metastatic castration-resistant prostate cancer (mCRPC) following progression on upfront androgen deprivation therapy (ADT) with androgen receptor pathway inhibitors (ARPI) for metastatic castration-sensitive prostate cancer (mCSPC).
 
Daniel Joseph Khalaf
Honoraria - Janssen
 
Liheng Chen
No Relationships to Disclose
 
Katherine Sunderland
No Relationships to Disclose
 
Joanna Vergidis
Honoraria - Astellas Pharma; Bayer; BMS; Merck; Pfizer
Consulting or Advisory Role - Bayer; BMS; Janssen
Travel, Accommodations, Expenses - Bayer; BMS; Merck
 
Krista Noonan
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; Bristol-Myers Squibb; Ipsen; Janssen; Janssen Oncology; Merck; Merck; Pfizer; Pfizer; Roche Canada; Sanofi
Speakers' Bureau - Merck
 
Daygen L. Finch
Honoraria - Astellas Pharma; Bayer; Janssen
Consulting or Advisory Role - Astellas Amgen BioPharama; AstraZeneca; Novartis; Pfizer
Speakers' Bureau - Pfizer
 
Muhammad Zulfiqar
Honoraria - Bayer
 
Kim N. Chi
Honoraria - Astellas Pharma; AstraZeneca; Bayer; Janssen; Merck; Roche
Consulting or Advisory Role - Amgen; Astellas Pharma; AstraZeneca; Bayer; Constellation Pharmaceuticals; Daiichi Sankyo; ESSA; Janssen; Merck; POINT Biopharma; Roche; Sanofi
Research Funding - Astellas Pharma (Inst); AstraZeneca (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); ESSA (Inst); Janssen (Inst); Merck (Inst); Novartis (Inst); Pfizer (Inst); Roche (Inst); Sanofi (Inst)
Expert Testimony - AstraZeneca; Novartis